drugset / Trial / NCT05474950

Minocycline Treatment for Cystoid Macular Edema

NCT05474950

Phase 1/2 Unknown 5 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

Timeline

Start
2019-01-01
Primary completion
2024-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 100 mg Oral

Indications